Teva’s Anti-IL-15 Candidate for Celiac Disease Receives FDA Fast Track Designation
Wednesday, May 28, 2025
Teva Pharmaceutical Industries has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to its investigational treatment, TEV-53408, for celiac disease.
Coeliac disease is a chronic autoimmune condition triggered by the consumption of gluten, a protein found in wheat, barley and rye. When individuals with the condition eat gluten, their immune system reacts by damaging the lining of the small intestine, which can lead to digestive issues, nutritional deficiencies and other health problems.
TEV-53408 is an experimental monoclonal antibody designed to target interleukin-15 (IL-15), a cytokine linked to immune reactions that cause intestinal damage in individuals with celiac disease. By blocking IL-15, the treatment aims to reduce inflammation and prevent symptoms, even when small amounts of gluten are accidentally consumed.
The therapy is currently being evaluated in a Phase 2a clinical trial involving adults who are following a gluten-free diet.
Fast Track designation is an FDA process that helps speed up the development and review of new medicines for serious conditions with unmet medical needs. Celiac disease is a long-term autoimmune disorder triggered by gluten, affecting around 1% of the global population. Although a gluten-free diet is currently the only treatment, many patients continue to suffer symptoms due to accidental exposure to gluten.
The ongoing Phase 2a trial (NCT06807463) is assessing the safety and effectiveness of TEV-53408. Teva’s latest development reflects its continued efforts to expand its pipeline of innovative therapies for autoimmune and immunological conditions.
Source: tevapharm.com
